CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Overall and Cause-Specific Mortality in Randomized Clinical Trials Comparing Percutaneous Interventions With Coronary Bypass Surgery: A Meta-analysis Left Ventricular Assist Devices for Lifelong Support Natural History of Spontaneous Coronary Artery Dissection With Spontaneous Angiographic Healing Advances in Coronary No-Reflow Phenomenon-a Contemporary Review Coronary Artery Calcium Is Associated with Left Ventricular Diastolic Function Independent of Myocardial Ischemia Long-Term Outcomes of Biodegradable Versus Second-Generation Durable Polymer Drug-Eluting Stent Implantations for Myocardial Infarction An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Management of Patients With NSTE-ACS: A Comparison of the Recent AHA/ACC and ESC Guidelines Effect of Aspirin on All-Cause Mortality in the Healthy Elderly Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations

Review Article2017 Nov 14;70(20):2536-2551.

JOURNAL:J Am Coll Cardiol. Article Link

Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1

Chang HM, Moudgil R, Yeh ETH et al. Keywords: cancer therapy; cardiomyopathy; cardiovascular complication; ischemia

ABSTRACT


Modern cancer therapy has successfully cured many cancers and converted a terminal illness into a chronic disease. Because cancer patients often have coexisting heart diseases, expert advice from cardiologists will improve clinical outcome. In addition, cancer therapy can also cause myocardial damage, induce endothelial dysfunction, and alter cardiac conduction. Thus, it is important for practicing cardiologists to be knowledgeable about the diagnosis, prevention, and management of the cardiovascular complications of cancer therapy. In this first part of a 2-part review, we will review cancer therapy-induced cardiomyopathy and ischemia. This review is based on a MEDLINE search of published data, published clinical guidelines, and best practices in major cancer centers. With the number of cancer survivors expanding quickly, the time has come for cardiologists to work closely with cancer specialists to prevent and treat cancer therapy-induced cardiovascular complications.